NICE Gives OK To Roche's Rozlytrek
Second Histology-Independent Drug To Win Backing
Executive Summary
Patients in England with NTRK fusion-positive solid tumors will now have access to Rozlytrek, the second cancer treatment that can be used to treat tumors regardless of where in the body they originated.
You may also be interested in...
English Funding Success For Roche’s Rozlytrek In NSCLC
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.